semaglutide and dementia Ozempic Linked to Significant Reduction in Dementia—Study Semaglutide Linked to Lower Dementia

doi: 10.1016/j.ijbiomac.2019.05.162

According to FDA labeling, nausea occurs in approximately 44% of patients on Wegovy (2.4 mg for weight management) and 15-20% on lower diabetes doses, with vomiting, diarrhea, constipation, and abdominal pain also common

As a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, GLP-2 has demonstrated exceptional efficacy in blood sugar control and weight loss

Generally, the recommended dosage ranges from 600 mg to 1,200 mg per week, with the possibility of gradually increasing it under medical supervision

Lower doses can sometimes reduce nausea, bloating, constipation, and other gastrointestinal side effects

Research focus is centered on how the integration of three distinct pathways influences the overall molecular signaling profile in controlled laboratory environments